11.14.26 -- Outsourced Pharma Newsletter - Best Of October

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

From supplier substitutions to release testing, raw-material decisions deserve the same sponsor scrutiny as the CDMOs that manufacture them.

The FDA calls on your CDMO; inspectors are fortified by data in AI models, and appear practically clairvoyant. “It won’t be like the ‘old days,’” says David Grote of GrayMatters Partners, an organization that advises on quality systems and inspection readiness. The agency earlier rolled out Elsa, an AI-enable data architecture. Now its added an impressive HALO - Harmonized AI & Lifecycle Operations for Data.

Operational excellence in drug manufacturing relies on a unified culture of integrity and proactive problem-solving. Aligned global teams strengthen the supply chain for reliable patient treatments.

Leverage the expertise of experienced project managers to select the right CDMO partner, mitigate risk, and drive your pharmaceutical program toward faster, more successful outcomes.

See how an automated capsule-filling approach addressed poor-flow APIs, improved operator safety, and supported fast scale-up for clinical supply needs.